144 related articles for article (PubMed ID: 36896578)
1. First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy.
Chakraborty R; Rosenbaum C; Kaur G; Bhutani D; Radhakrishnan J; Mapara MY; Maurer M; Lentzsch S
Br J Haematol; 2023 Jun; 201(5):913-916. PubMed ID: 36896578
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW
Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996
[TBL] [Abstract][Full Text] [Related]
3. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
Suzuki K; Wechalekar AD; Kim K; Shimazaki C; Kim JS; Ikezoe T; Min CK; Zhou F; Cai Z; Chen X; Iida S; Katoh N; Fujisaki T; Shin HJ; Tran N; Qin X; Vasey SY; Tromp B; Weiss BM; Comenzo RL; Kastritis E; Lu J
Ann Hematol; 2023 Apr; 102(4):863-876. PubMed ID: 36862168
[TBL] [Abstract][Full Text] [Related]
4. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
Oubari S; Hegenbart U; Schoder R; Steinhardt M; Papathanasiou M; Rassaf T; Thimm A; Hagenacker T; Naser E; Duhrsen U; Reinhardt HC; Kortum M; Agis H; Schonland S; Carpinteiro A
Haematologica; 2024 Jan; 109(1):220-230. PubMed ID: 37439344
[TBL] [Abstract][Full Text] [Related]
5. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
Zhang Y; Duncanson L; Brayer J; Reu F; Hansen D; Alsina M; Nishihori T; Ochoa-Bayona J; Liu H; Shain K; Thompson Z; Baz R; Blue B
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e770-e776. PubMed ID: 35504808
[TBL] [Abstract][Full Text] [Related]
6. Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study.
Kumar S; Dispenzieri A; Bhutani D; Gertz M; Wechalekar A; Palladini G; Comenzo R; Fonseca R; Jaccard A; Kastritis E; Schönland S; la Porte C; Pei H; Tran N; Merlini G
Amyloid; 2023 Sep; 30(3):268-278. PubMed ID: 36779691
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Palladini G; Kastritis E; Maurer MS; Zonder J; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Bumma N; Kaufman JL; Medvedova E; Kovacsovics T; Rosenzweig M; Sanchorawala V; Qin X; Vasey SY; Weiss BM; Vermeulen J; Merlini G; Comenzo RL
Blood; 2020 Jul; 136(1):71-80. PubMed ID: 32244252
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
Blair HA
Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
[TBL] [Abstract][Full Text] [Related]
9. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.
Minnema MC; Dispenzieri A; Merlini G; Comenzo RL; Kastritis E; Wechalekar AD; Grogan M; Witteles R; Ruberg FL; Maurer MS; Tran N; Qin X; Vasey SY; Weiss BM; Vermeulen J; Jaccard A
JACC CardioOncol; 2022 Nov; 4(4):474-487. PubMed ID: 36444227
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.
Venner CP; Lane T; Foard D; Rannigan L; Gibbs SD; Pinney JH; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Blood; 2012 May; 119(19):4387-90. PubMed ID: 22331187
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
[TBL] [Abstract][Full Text] [Related]
12. [Daratumumab for the treatment of primary systemic amyloidosis: a multicenter retrospective analysis].
Liu Y; Huang XH; Duan WB; Fang BJ; Huang DP; Zhang YH; Xu L; Zhang HY; Zhang H; Wen L; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2021 Nov; 60(11):987-992. PubMed ID: 34689520
[No Abstract] [Full Text] [Related]
13. Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib.
Shen KN; Miao HL; Zhang CL; Feng J; Zhang L; Cao XX; Zhou DB; Wei S; Li J
Leuk Lymphoma; 2021 Apr; 62(4):874-882. PubMed ID: 33215569
[TBL] [Abstract][Full Text] [Related]
14. Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival.
Basset M; Milani P; Foli A; Nuvolone M; Benvenuti P; Nanci M; Fabris F; Bellofiore C; Merlini G; Palladini G
Blood; 2022 Nov; 140(18):1964-1971. PubMed ID: 35772003
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Sanchorawala V; Palladini G; Minnema MC; Jaccard A; Lee HC; Gibbs S; Mollee P; Venner C; Lu J; Schönland S; Gatt M; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Chauveau D; Gries KS; Fastenau J; Tran NP; Qin X; Vasey SY; Weiss BM; Vermeulen J; Ho KF; Merlini G; Comenzo RL; Kastritis E; Wechalekar AD
Am J Hematol; 2022 Jun; 97(6):719-730. PubMed ID: 35293006
[TBL] [Abstract][Full Text] [Related]
16. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
[TBL] [Abstract][Full Text] [Related]
17. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
Kastritis E; Gavriatopoulou M; Roussou M; Fotiou D; Ziogas DC; Migkou M; Eleutherakis-Papaiakovou E; Panagiotidis I; Kanellias N; Psimenou E; Papadopoulou E; Pamboucas C; Manios E; Gakiopoulou H; Ntalianis A; Tasidou A; Giannouli S; Terpos E; Dimopoulos MA
Blood Cancer J; 2017 Jun; 7(6):e570. PubMed ID: 28622303
[TBL] [Abstract][Full Text] [Related]
18. A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.
Bellofiore C; Benvenuti P; Mina R; Basset M; Foli A; Nanci M; Nuvolone M; Guida G; Attanasio A; Mussinelli R; Mangiacavalli S; Cartia CS; Masoni V; Palumbo M; Cani L; Oliva S; Consoli U; Conticello C; Di Raimondo F; Arcaini L; Bringhen S; Merlini G; Palladini G; Milani P
Hematol Oncol; 2024 Jul; 42(4):e3289. PubMed ID: 38824453
[TBL] [Abstract][Full Text] [Related]
19. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
[TBL] [Abstract][Full Text] [Related]
20. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen.
Dumas B; Yameen H; Sarosiek S; Sloan JM; Sanchorawala V
Amyloid; 2020 Dec; 27(4):244-249. PubMed ID: 32551974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
